BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 10741925)

  • 1. Chemoembolization of hepatic metastases from intestinal neuroendocrine tumours.
    Kirchhoff T; Chavan A; Galanski M
    Eur J Gastroenterol Hepatol; 2000 Feb; 12(2):141-3. PubMed ID: 10741925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic surgery for metastases from neuroendocrine tumors.
    Sarmiento JM; Que FG
    Surg Oncol Clin N Am; 2003 Jan; 12(1):231-42. PubMed ID: 12735141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytotoxic treatment including embolization/chemoembolization for neuroendocrine tumours.
    Toumpanakis C; Meyer T; Caplin ME
    Best Pract Res Clin Endocrinol Metab; 2007 Mar; 21(1):131-44. PubMed ID: 17382269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural history of liver metastasis of gastroenteropancreatic neuroendocrine tumors: place for chemoembolization.
    Proye C
    World J Surg; 2001 Jun; 25(6):685-8. PubMed ID: 11376397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intra-arterial hepatic chemoembolization in liver metastases from neuroendocrine tumors: a phase II study.
    Fiorentini G; Rossi S; Bonechi F; Vaira M; De Simone M; Dentico P; Bernardeschi P; Cantore M; Guadagni S
    J Chemother; 2004 Jun; 16(3):293-7. PubMed ID: 15330328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two-phase study of hepatic artery vascular occlusion with microencapsulated cisplatin in patients with liver metastases from neuroendocrine tumors.
    Diamandidou E; Ajani JA; Yang DJ; Chuang VP; Brown CA; Carrasco HC; Lawrence DD; Wallace S
    AJR Am J Roentgenol; 1998 Feb; 170(2):339-44. PubMed ID: 9456942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum pancreastatin levels predict response to hepatic artery chemoembolization and somatostatin analogue therapy in metastatic neuroendocrine tumors.
    Desai DC; O'Dorisio TM; Schirmer WJ; Jung SS; Khabiri H; Villanueva V; Martin EW
    Regul Pept; 2001 Jan; 96(3):113-7. PubMed ID: 11111016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic treatment of neuroendocrine tumors with hepatic metastases.
    Demirkan BH; Eriksson B
    Turk J Gastroenterol; 2012; 23(5):427-37. PubMed ID: 23161287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of hepatic metastases of neuroendocrine malignancies: a 10-year experience.
    Dejong CH; Parks RW; Currie E; Piris J; Redhead DN; Garden OJ
    J R Coll Surg Edinb; 2002 Apr; 47(2):495-9. PubMed ID: 12018694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of advanced neuroendocrine tumors with hepatic metastasis.
    Khasraw M; Gill A; Harrington T; Pavlakis N; Modlin I
    J Clin Gastroenterol; 2009 Oct; 43(9):838-47. PubMed ID: 19654558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors.
    Ho AS; Picus J; Darcy MD; Tan B; Gould JE; Pilgram TK; Brown DB
    AJR Am J Roentgenol; 2007 May; 188(5):1201-7. PubMed ID: 17449759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver (RETNET): study protocol for a randomized controlled trial.
    Chen JX; Wileyto EP; Soulen MC
    Trials; 2018 Jul; 19(1):390. PubMed ID: 30016989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic and regional nonsurgical therapy--what is the optimal strategy for metastatic neuroendocrine cancer?
    Nakakura EK; Venook AP; Bergsland EK
    Surg Oncol Clin N Am; 2007 Jul; 16(3):639-51, x. PubMed ID: 17606198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy for gastro-enteropancreatic endocrine tumours.
    O'Toole D; Hentic O; Corcos O; Ruszniewski P
    Neuroendocrinology; 2004; 80 Suppl 1():79-84. PubMed ID: 15477723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic arterial embolization in patients with neuroendocrine tumors.
    Del Prete M; Fiore F; Modica R; Marotta V; Marciello F; Ramundo V; Di Sarno A; Carratù A; di Roseto Cde L; Tafuto S; Tatangelo F; Baldelli R; Colao A; Faggiano A;
    J Exp Clin Cancer Res; 2014 May; 33(1):43. PubMed ID: 24887262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors.
    Osborne DA; Zervos EE; Strosberg J; Boe BA; Malafa M; Rosemurgy AS; Yeatman TJ; Carey L; Duhaine L; Kvols LK
    Ann Surg Oncol; 2006 Apr; 13(4):572-81. PubMed ID: 16511671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic arterial chemoembolization with streptozotocin in patients with metastatic digestive endocrine tumours.
    Dominguez S; Denys A; Madeira I; Hammel P; Vilgrain V; Menu Y; Bernades P; Ruszniewski P
    Eur J Gastroenterol Hepatol; 2000 Feb; 12(2):151-7. PubMed ID: 10741928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic arterial chemoembolization for metastatic neuroendocrine tumors.
    Perry LJ; Stuart K; Stokes KR; Clouse ME
    Surgery; 1994 Dec; 116(6):1111-6; discussion 1116-7. PubMed ID: 7985095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment options for unresectable neuroendocrine liver metastases.
    John BJ; Davidson BR
    Expert Rev Gastroenterol Hepatol; 2012 Jun; 6(3):357-69. PubMed ID: 22646257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interventional treatment of neuroendocrine liver metastases.
    Knigge U; Hansen CP; Stadil F
    Surgeon; 2008 Aug; 6(4):232-9. PubMed ID: 18697366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.